vs
Side-by-side financial comparison of Oportun Financial Corp (OPRT) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Oportun Financial Corp is the larger business by last-quarter revenue ($247.7M vs $158.6M, roughly 1.6× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 1.4%, a 69.8% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -1.3%).
Oportun Financial Corp is a US-based fintech firm that provides accessible, responsible financial services including personal loans, credit cards, and savings products to underserved low-to-moderate income consumers, many with limited or no credit history, leveraging proprietary AI underwriting to deliver fair terms while mitigating operational risk.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
OPRT vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.7M | $158.6M |
| Net Profit | $3.4M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 2.6% | 70.2% |
| Net Margin | 1.4% | 71.2% |
| Revenue YoY | -1.3% | 3661.1% |
| Net Profit YoY | -61.0% | 528.0% |
| EPS (diluted) | $0.07 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.7M | — | ||
| Q3 25 | $238.7M | — | ||
| Q2 25 | $234.3M | — | ||
| Q1 25 | $235.9M | $158.6M | ||
| Q4 24 | $250.9M | $22.6M | ||
| Q3 24 | $250.0M | — | ||
| Q2 24 | $250.4M | — | ||
| Q1 24 | $250.5M | — |
| Q4 25 | $3.4M | — | ||
| Q3 25 | $5.2M | — | ||
| Q2 25 | $6.9M | — | ||
| Q1 25 | $9.8M | $112.9M | ||
| Q4 24 | $8.7M | $-10.5M | ||
| Q3 24 | $-30.0M | — | ||
| Q2 24 | $-31.0M | — | ||
| Q1 24 | $-26.4M | — |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 5.6% | 70.2% | ||
| Q4 24 | 89.6% | -60.4% | ||
| Q3 24 | -15.8% | — | ||
| Q2 24 | -19.6% | — | ||
| Q1 24 | -12.2% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 4.1% | 71.2% | ||
| Q4 24 | 200.1% | -46.4% | ||
| Q3 24 | -12.0% | — | ||
| Q2 24 | -12.4% | — | ||
| Q1 24 | -10.6% | — |
| Q4 25 | $0.07 | — | ||
| Q3 25 | $0.11 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.21 | $1.90 | ||
| Q4 24 | $0.26 | $-0.15 | ||
| Q3 24 | $-0.75 | — | ||
| Q2 24 | $-0.78 | — | ||
| Q1 24 | $-0.68 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $105.5M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $390.1M | $350.1M |
| Total Assets | $3.3B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $105.5M | — | ||
| Q3 25 | $104.6M | — | ||
| Q2 25 | $96.8M | — | ||
| Q1 25 | $78.5M | $274.8M | ||
| Q4 24 | $60.0M | $128.0M | ||
| Q3 24 | $71.8M | — | ||
| Q2 24 | $72.9M | — | ||
| Q1 24 | $69.2M | — |
| Q4 25 | $390.1M | — | ||
| Q3 25 | $383.9M | — | ||
| Q2 25 | $376.0M | — | ||
| Q1 25 | $366.1M | $350.1M | ||
| Q4 24 | $353.8M | $229.0M | ||
| Q3 24 | $327.6M | — | ||
| Q2 24 | $354.1M | — | ||
| Q1 24 | $382.0M | — |
| Q4 25 | $3.3B | — | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $3.2B | — | ||
| Q1 25 | $3.2B | $406.9M | ||
| Q4 24 | $3.2B | $271.6M | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $3.3B | — | ||
| Q1 24 | $3.3B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $413.4M | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | 121.45× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $413.4M | — | ||
| Q3 25 | $99.0M | — | ||
| Q2 25 | $104.5M | — | ||
| Q1 25 | $101.0M | $131.8M | ||
| Q4 24 | $393.5M | $-23.2M | ||
| Q3 24 | $108.5M | — | ||
| Q2 24 | $107.7M | — | ||
| Q1 24 | $85.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 121.45× | — | ||
| Q3 25 | 19.05× | — | ||
| Q2 25 | 15.20× | — | ||
| Q1 25 | 10.34× | 1.17× | ||
| Q4 24 | 45.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
